BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9572991)

  • 1. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome.
    Warzocha K; Ribeiro P; Bienvenu J; Roy P; Charlot C; Rigal D; Coiffier B; Salles G
    Blood; 1998 May; 91(10):3574-81. PubMed ID: 9572991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.
    Seidemann K; Zimmermann M; Book M; Meyer U; Burkhardt B; Welte K; Reiter A; Stanulla M
    J Clin Oncol; 2005 Nov; 23(33):8414-21. PubMed ID: 16293872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P
    Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphotoxin alpha (LTA) polymorphism is associated with prognosis of non-Hodgkin's lymphoma in a Chinese population.
    Zhang Y; Chen MB; Zhou XY; Hong XN
    PLoS One; 2013; 8(6):e66411. PubMed ID: 23840460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher LPS-stimulated TNF-alpha mRNA levels in peripheral blood mononuclear cells from non-Hodgkin's lymphoma patients.
    Baseggio L; Bienvenu J; Charlot C; Picollet J; Felman P; Coiffier B; Salles G
    Exp Hematol; 2001 Mar; 29(3):330-8. PubMed ID: 11274761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas].
    Kalinka E; Juszczyński P; Woszczek G; Borowiec M; Robak T; Kowalski ML; Biliński P; Coiffier B; Salles G; Warzocha K
    Przegl Lek; 2005; 62(12):1422-6. PubMed ID: 16786764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
    Cerhan JR; Liu-Mares W; Fredericksen ZS; Novak AJ; Cunningham JM; Kay NE; Dogan A; Liebow M; Wang AH; Call TG; Habermann TM; Ansell SM; Slager SL
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3161-9. PubMed ID: 18990758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
    Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS
    Blood; 1995 Apr; 85(7):1727-35. PubMed ID: 7535586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor alpha-308 and Lymphotoxin alpha+252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt.
    Ibrahim A; Abdel Rahman H; Khorshied M; Sami R; Nasr N; Khorshid O
    Leuk Res; 2012 Jun; 36(6):694-8. PubMed ID: 22177457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between tumor necrosis factor genetic polymorphisms and acute lymphocytic leukemia].
    Zhao HY; Chen YX; Lin XB; Zhong XY; Zhong LY; Ou RM; Jiang WQ; Guan ZZ
    Ai Zheng; 2003 Aug; 22(8):861-6. PubMed ID: 12917036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas.
    Warzocha K; Ribeiro P; Renard N; Bienvenu J; Charlot C; Coiffier B; Salles G
    Cancer Immunol Immunother; 2000 Nov; 49(9):469-75. PubMed ID: 11092613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.
    Morabito F; Hohaus S; Mammi C; Marcheselli L; Gentile M; Merli F; Montanini A; Stelitano C; La Sala A; Scalone R; Voso MT; Luminari S; Iannitto E; Gobbi P; Federico M
    Leuk Lymphoma; 2012 Mar; 53(3):406-10. PubMed ID: 21916526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.
    Nowak J; Kalinka-Warzocha E; Juszczynski P; Bilinski P; Mika-Witkowska R; Zajko M; Bienvenu J; Coiffier B; Salles G; Warzocha K
    Genes Chromosomes Cancer; 2007 May; 46(5):500-7. PubMed ID: 17311253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
    Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.